Navigation Links
Baxter Announces Licensing Agreement for Innocoll's Gentamicin Surgical Implant in the United States
Date:8/25/2008

ietary collagen-based technologies, CollaRx(R) and Liquicoll(R). Innocoll's lead product, Gentamicin Surgical Implant for the treatment and prevention of SSIs, is approved for sale in 49 countries in Europe, Latin America, the Middle East, Africa and Asia. The gentamicin surgical implant is currently in Phase III development in the United States for the prevention of SSIs. Other late stage pharmaceutical products in Innocoll's development pipeline include CollaRx Gentamicin Topical for the treatment and prevention of infected diabetic foot ulcers and CollaRx Bupivacaine Implant for the management of post-operative pain, both of which are currently in Phase II development. For more information, please visit http://www.innocollinc.com.

About Baxter

Baxter Healthcare Corporation is the principal U.S. operating subsidiary of Baxter International Inc. (NYSE: BAX). Baxter International Inc. develops, manufactures and markets products that save and sustain the lives of people with hemophilia, immune disorders, cancer, infectious diseases, kidney disease, trauma, and other chronic and acute medical conditions. As a global, diversified healthcare company, Baxter applies a unique combination of expertise in medical devices, pharmaceuticals and biotechnology to create products that advance patient care worldwide.

This release includes forward-looking statements regarding Baxter's expectations related to its licensing agreement with Innocoll and the timing of U.S. regulatory approval of Innocoll's gentamicin surgical implant. These statements are based on assumptions about many important factors, including the following, which could cause actual results to differ materially from thos
'/>"/>

SOURCE Baxter Healthcare Corporation
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Baxter Declares Quarterly Dividend
2. Baxter Raises Full-Year 2008 Outlook Following Strong Second-Quarter Financial Results
3. Bioniche Pharma Acquires Baxters ENLON(R) and ENLON-PLUS(R)
4. Baxters Board of Directors Declares Quarterly Dividend
5. Baxter Reports Solid First Quarter Financial Results and Raises Full-Year Outlook
6. Baxters V-Link Luer-Activated Device With VitalShield Protective Coating Now Available For Hospitals
7. Baxter Announces FDA Approval of ARTISS Slow-Setting Fibrin Sealant in Treatment of Burn Patients
8. Baxters Board of Directors Approves New Share Repurchase Authorization of $2 Billion
9. Baxter and Its Foundation Contribute Nearly $53 Million in 2007 to Address Critical Needs Locally and Globally
10. Baxter to Proceed With Recall of Remaining Heparin Sodium Vial Products
11. Baxter Declares Quarterly Dividend
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)...  Bill Jacobs Automotive, a group of car dealerships headquartered in ... Heartland Blood Center and offering free oil change coupons for ... Saturday, Jan. 18 at the Bill Jacobs Cadillac and Chevrolet ... http://photos.prnewswire.com/prnh/20140115/MN46637 )  The Bill Jacobs Auto ...
(Date:1/15/2014)... Cynvenio, a cancer diagnostics company focused on ... of tumor cells in the bloodstream, today announced that ... support application powered by CollabRx, Inc. , Available ... Therapy Finder will provide breast cancer patients and their ...
(Date:1/15/2014)... IPSWICH, England , January 15, 2014 ... to win races on the Formula 1 track could help ... between McLaren Applied Technologies (MAT), Stowhealth (a GP surgery based ... funded by healthcare provider Simplyhealth. Telemetry technology, which ...
(Date:1/15/2014)... DTS Language Services, Inc . is pleased to announce ... organizations who need document translations. Clients will now have ... in advance with a selection of nearly 50 life science ... critical factor in clinical and scientific fields, and decrease the ...
Breaking Biology Technology:Join the Bill Jacobs Auto blood drive and receive a free oil change 2Cynvenio Offers New Breast Cancer Therapy Finder Application for its ClearID Breast Cancer Genomic Test 2Cynvenio Offers New Breast Cancer Therapy Finder Application for its ClearID Breast Cancer Genomic Test 3Formula 1 Technology Tackles Obesity in Unique Healthcare Partnership 2Formula 1 Technology Tackles Obesity in Unique Healthcare Partnership 3Formula 1 Technology Tackles Obesity in Unique Healthcare Partnership 4DTS Improves Efficiency for Life Science Document Translations 2
... Call on Friday, March 13, 2009 at 8:30am ... Inc. (Nasdaq: KERX ), a biopharmaceutical ... of medically important, novel pharmaceutical products for the ... cancer (the "Company"), today announced its results for ...
... Burrill & Company Collaborating on Strategic Next Steps ... Developer Tower Investments, LLC ("Tower"), and San Francisco-based ... announced a formal partnership with aims of advancing ... and funding related to the "shovel-ready" BioBusiness Park ...
... , - ThromboGenics Reports Pre-Tax Profit ... ThromboGenics NV (Euronext Brussels: THR), a biotechnology company,focused on the ... difference to patient care in a number of important therapeutic,areas, ... for the,full year ending December 31, 2008. , ...
Cached Biology Technology:Keryx Biopharmaceuticals, Inc. Announces Fourth Quarter and Year-End 2008 Financial Results 2Keryx Biopharmaceuticals, Inc. Announces Fourth Quarter and Year-End 2008 Financial Results 3Keryx Biopharmaceuticals, Inc. Announces Fourth Quarter and Year-End 2008 Financial Results 4Keryx Biopharmaceuticals, Inc. Announces Fourth Quarter and Year-End 2008 Financial Results 5Keryx Biopharmaceuticals, Inc. Announces Fourth Quarter and Year-End 2008 Financial Results 6Elk Run Developers Announce Partnership with Leading Life Sciences Firm 2Elk Run Developers Announce Partnership with Leading Life Sciences Firm 3Elk Run Developers Announce Partnership with Leading Life Sciences Firm 4ThromboGenics Announces Business Update and 2008 Full Year Results 2ThromboGenics Announces Business Update and 2008 Full Year Results 3ThromboGenics Announces Business Update and 2008 Full Year Results 4ThromboGenics Announces Business Update and 2008 Full Year Results 5ThromboGenics Announces Business Update and 2008 Full Year Results 6
(Date:4/20/2014)... gift of germsgerms that help to kick-start the ... off infection, may paradoxically interrupt a newborn,s own ... to dangerous pathogens. , A new animal ... of Philadelphia (CHOP) sheds light on immunology in ... crucial role in fostering the rapid production of ...
(Date:4/20/2014)... crop residue to make ethanol and other biofuels reduces ... gasoline, according to a study published today in the ... by a University of Nebraska-Lincoln team of researchers cast ... meet federal mandates to ramp up ethanol production and ... stalks, leaves and cobs in cornfields after harvest -- ...
(Date:4/18/2014)... have used techniques like X-ray crystallography and nuclear magnetic ... atomic structure of molecules, but such efforts have long ... quantities of a specific molecule and often in ordered ... all but impossible to peer into the structure of ... may soon be a thing of the past. ...
Breaking Biology News(10 mins):Study of gut microbes, antibiotics: Clues to improving immunity in premature infants 2Study casts doubt on climate benefit of biofuels from corn residue 2Study casts doubt on climate benefit of biofuels from corn residue 3MRI, on a molecular scale 2MRI, on a molecular scale 3
... DNA damage resets the cellular circadian clock, suggesting links ... the propensity for cancer. , Their work, reported June ... Science, implies a protective dimension for the biological clock ... a sweeping role in the rhythms and activities of ...
... Scientists from The University of Tokyo announce today that gibbons, ... not carry a major obesity gene that is present in ... is due to a genetic mis-shuffling event that occurred approximately ... the April issue of the scientific journal Genome Research ...
... containing platinum, Virginia Commonwealth University Massey Cancer Center researchers have ... in HIV and cancer. , The findings may help researchers ... targeting proteins known as zinc fingers. , In the May ... that a zinc finger protein, known as HIV NCp7, can ...
Cached Biology News:Novel connection found between biological clock and cancer 2Major obesity gene is 'lost in the shuffle' 2New protein target may advance design of HIV and cancer drugs 2
Mouse monoclonal antibody raised against a partial recombinant TTC3. NCBI Entrez Gene ID = TTC3...
Mouse monoclonal antibody raised against a partial recombinant DENR. NCBI Entrez Gene ID = DENR...
Mouse monoclonal antibody raised against a partial recombinant CRKRS. NCBI Entrez Gene ID = CRKRS...
... Perm/Wash Buffer I can be used in ... to permeabilize cells and to serve as ... Because saponin-mediated cell permeabilization is a reversible ... cells in the presence of saponin during ...
Biology Products: